Stockscreener 앱 받기
13.65
2.64%
-0.37
시간 외 거래:
13.65
전일 마감가:
$14.02
열려 있는:
$13.89
하루 거래량:
546.34K
Relative Volume:
0.53
시가총액:
$594.96M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.6608
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
-6.83%
1개월 성능:
+32.14%
6개월 성능:
-79.90%
1년 성능:
-76.30%
1일 변동 폭
$13.57
$14.22
1주일 범위
$13.43
$14.80
52주 변동 폭
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
13.65 | 594.96M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by DAFNA Capital Management LLC - MarketBeat
HC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00 - MarketBeat
What is Leerink Partnrs' Estimate for KROS FY2025 Earnings? - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect - ACCESS Newswire
Investors who lost money on Keros Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigationKROS - ACCESS Newswire
Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st
Keros Therapeutics (KROS) to Release Quarterly Earnings on Wednesday - MarketBeat
Barclays PLC Boosts Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
JPMorgan Chase & Co. Acquires Significant Stake in Keros Therapeutics Inc. - GuruFocus
Alkeon Capital Management LLC Trims Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Reinforces Commitment to Maximizing Stockholder Value - GlobeNewswire
Keros Reinforces Commitment to Maximizing Stockholder Value | KROS Stock News - Stock Titan
ADAR1 Capital Management urges Keros Therapeutics for board change - Seeking Alpha
Keros Therapeutics Stockholder ADAR1 Seeks Business Restructuring Alleging Prolonged Underperformance - marketscreener.com
ADAR1 Capital Management Calls For Keros Therapeutics To Restructure Business, Reduce Headcount - marketscreener.com
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Yahoo Finance
Keros Therapeutics stock target cut to $25 at H.C. Wainwright By Investing.com - Investing.com India
Keros Therapeutics stock target cut to $25 at H.C. Wainwright - Investing.com
KROS Stock Target Cut by Analyst Amid Trial Setback | KROS Stock News - GuruFocus
Braidwell LP Raises Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Wells Fargo & Company MN Raises Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
MetLife Investment Management LLC Purchases 1,027 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics Reports Strong Q1 2025 Results - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Tower Research Capital LLC TRC - MarketBeat
Boxer Capital Management LLC Invests $3.96 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Keros Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
KROS Reports Strong Q1 Earnings Boosted by License Agreement | KROS Stock News - GuruFocus
Keros Therapeutics Swings to Massive $148M Profit as Phase 1 Trial Hits Key Goals - Stock Titan
(KROS) Long Term Investment Analysis - news.stocktradersdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Nebula Research & Development LLC Has $1.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
544,001 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Lynx1 Capital Management LP - MarketBeat
Keros Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Was Keros Therapeutics Inc (KROS)’s session last reading good? - uspostnews.com
Implied Volatility Surging for Keros Therapeutics Stock Options - Yahoo Finance
Keros Therapeutics Inc [KROS] 10% Owner makes an insider purchase of 934,258 shares worth 9.46 million. - knoxdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Russell Investments Group Ltd. - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $40.33 - Defense World
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.84%
0.15%
자본화:
|
볼륨(24시간):